Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Acquisitions & Divestments: 2012-2025

Historic Change in Acquisitions & Divestments for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $272.1 million.

  • Agios Pharmaceuticals' Change in Acquisitions & Divestments rose 72.67% to $272.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $931.1 million, marking a year-over-year increase of 8.97%. This contributed to the annual value of $818.4 million for FY2024, which is 21.30% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Change in Acquisitions & Divestments is $272.1 million, which was up 23.32% from $220.6 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Acquisitions & Divestments ranged from a high of $368.7 million in Q1 2024 and a low of $134.0 million during Q1 2021.
  • For the 3-year period, Agios Pharmaceuticals' Change in Acquisitions & Divestments averaged around $206.7 million, with its median value being $186.2 million (2023).
  • In the last 5 years, Agios Pharmaceuticals' Change in Acquisitions & Divestments spiked by 147.84% in 2022 and then tumbled by 55.06% in 2023.
  • Agios Pharmaceuticals' Change in Acquisitions & Divestments (Quarterly) stood at $336.9 million in 2021, then crashed by 40.97% to $198.9 million in 2022, then fell by 6.38% to $186.2 million in 2023, then declined by 19.36% to $150.1 million in 2024, then spiked by 72.67% to $272.1 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $272.1 million for Q3 2025, versus $220.6 million for Q2 2025 and $288.3 million for Q1 2025.